Scinovex
review Open AccessTop 1% cited

Triple negative breast cancer: unmet medical needs

Breast Cancer Research and Treatment · 2010 · Vol. 125(3) · pp. 627–636
Sumanta K. PalBarrett H. ChildsMark D. Pegram
PARP inhibition in cancer therapyBreast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesTriple-negative breast cancerMedicineBreast cancerCetuximabOncologyInternal medicineSunitinibErlotinibEpidermal growth factor receptorBevacizumab

MeSH terms

CetuximabErlotinib HydrochlorideAntibodies, MonoclonalAntineoplastic AgentsBreast NeoplasmsFemaleHumansPhenotypePoly(ADP-ribose) PolymerasesQuinazolinesReceptors, EstrogenReceptors, ProgesteroneGene Expression Regulation, NeoplasticTreatment OutcomeDisease-Free Survival

Funding

  • Sanofi
Citations
325
FWCI
11.96
field-weighted impact
References
76
Percentile
99%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Triple negative breast cancer: unmet medical needs · Scinovex